Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Merus NV (MRUS)
NASDAQ:MRUS
Merus (MRUS) Stock Price & Analysis
271 Followers
MRUS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$19.81 - $61.61
Previous Close$55.29
Volume518.19K
Average Volume (3M)1.10M
Market Cap
$3.66B
Enterprise Value$3.32B
Total Cash (Recent Filing)$354.38M
Total Debt (Recent Filing)$12.16M
Price to Earnings (P/E)―
Beta1.02
Next Earnings
Aug 05, 2024EPS Estimate
-$0.76Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.72
Shares Outstanding58,687,551
10 Day Avg. Volume843,100
30 Day Avg. Volume1,095,351
Standard Deviation0.18
R-Squared0.10
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)9.08
Price to Sales (P/S)360.04
Price to Cash Flow (P/CF)-22.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue75.55
Enterprise Value/Gross Profit75.55
Enterprise Value/Ebitda-47.79
Forecast
1Y Price Target
$86.14Price Target Upside55.80% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
Merus News
PremiumCompany Announcements
Merus N.V. Appoints New CMO, Announces Executive Changes
Bulls Say, Bears Say
Bulls Say
Clinical TrialsMerus dosed the first petosemtamab patient in a n=40 patient Ph2 trial for 2L metastatic colorectal cancer (mCRC) in combination with chemotherapy.
Management And StrategyManagement commented these changes to the management team are a reflection of the company transitioning to late-stage development and ensuring the right team is in place to optimize the commercial opportunity for petosemtamab and the pipeline.
Market OpportunityThe total addressable market could exceed $10 billion by 2034, suggesting the potential for multiple blockbuster drugs.
Bears Say
Clinical TrialsBicara's updated Phase 1/1b data for BCA101 seem weaker vs Merus' MCLA-158 on Overall Response Rate (ORR).
Efficacy ConcernsAmong HPV negative patients, Merus showed 65% Overall response rate (ORR) for MCLA-158 + pembrolizumab vs 54% for Bicara + pembrolizumab, a major advantage to Merus, in our view.
ManagementThe stock reacted negatively in the pre-market, trading on speculation that the departures could suggest a failed transaction.
---
Ownership Overview
6.30% Insiders
11.07% Mutual Funds
1.95% Other Institutional Investors
80.68% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
MRUS FAQ
What was Merus NV’s price range in the past 12 months?
Merus NV lowest stock price was $19.80 and its highest was $61.61 in the past 12 months.
What is Merus NV’s market cap?
Currently, no data Available
When is Merus NV’s upcoming earnings report date?
Merus NV’s upcoming earnings report date is Aug 05, 2024 which is in 13 days.
How were Merus NV’s earnings last quarter?
Merus NV released its earnings results on May 08, 2024. The company reported -$0.59 earnings per share for the quarter, beating the consensus estimate of -$0.806 by $0.216.
Is Merus NV overvalued?
According to Wall Street analysts Merus NV’s price is currently Undervalued.
Does Merus NV pay dividends?
Merus NV does not currently pay dividends.
What is Merus NV’s EPS estimate?
Merus NV’s EPS estimate is -$0.76.
How many shares outstanding does Merus NV have?
Merus NV has 66,237,550 shares outstanding.
What happened to Merus NV’s price movement after its last earnings report?
Merus NV reported an EPS of -$0.59 in its last earnings report, beating expectations of -$0.806. Following the earnings report the stock price went down -4.183%.
Which hedge fund is a major shareholder of Merus NV?
Among the largest hedge funds holding Merus NV’s share is Deerfield Management Company, LP. It holds Merus NV’s shares valued at 119M.
---
Merus Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$86.14 (55.80% Upside)
$86.14 (55.80% Upside)
Blogger Sentiment
Bullish
MRUS Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 70.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $792.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.7%
Last 30 Days ▲ 12.8%
Last 30 Days ▲ 12.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
104.70%
12-Months-Change
Fundamentals
Return on Equity
-52.79%
Trailing 12-Months
Asset Growth
47.14%
Trailing 12-Months
Company Description
Merus NV
Merus NV is a clinical-stage immune-oncology company, which engages in the discovery and development of bi-specific antibody therapeutics. Its pipeline includes Biclonics for solid and hematological tumors. The company was founded by Ton Logtenberg on June 16, 2003 and is headquartered in Utrecht, Netherlands.
---
MRUS Stock 12 Month Forecast
Average Price Target
$86.14
▲(55.80% Upside)
Technical Analysis
Best Analysts Covering MRUS
1 Year
1 Year Success Rate
12/13 ratings generated profit
1 Year Average Return
+65.26%
assigned a buy rating 2 months ago
Copying Etzer Darout's trades and holding each position for 1 Year would result in 92.31% of your transactions generating a profit, with an average return of +65.26% per trade.
---